Nancy
OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug), OBI-998 (SSEA-4 ADC) and the glycosphingolipid cancer antigens, Globo H and SSEA-4. Taipei, Taiwan. April 06, 2021 …
OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland
1. Date of occurrence of the event: Mar 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. …
The Board of Directors resolved to hold 2021 Annual General Meeting
1. Date of the board of directors resolution: Mar 12, 2021 2. Date for convening the shareholders’ meeting: Jun 21, 2021 3. Location for convening the shareholders’ meeting: Masterlink Securities …
Announcement of not Distributing Dividends in 2020
1. Date of the board of directors resolution: Mar 12, 2021 2. Year or quarter which dividends belong to: Year of 2020 3. Period which dividends belong to: Jan 01, …
Announcement of 2020 Consolidated Financial Report
1. Date of the financial reports submitted to the board of directors or approved by the board of directors: Mar 12, 2021 2. Date of the financial reports approved by …
OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations of Mexico
1. Date of occurrence of the event: Mar 12, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. …
OBI licensed “OBI-858 Novel Botulinum Toxin Preparation” Intellectual Property Right of Global Aesthetic Medicine to OBIGEN Pharma, Inc.
1. Date of occurrence of the event: Feb 23, 2021 2. Counterparty to the contract or commitment: OBIGEN Pharma, Inc. 3. Relationship with the Company: None 4. Starting and ending …
OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa
1. Date of occurrence of the event: Feb 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. …
Mr. Michael Chang and five other executives received an acquittal for insider trading case at second instance by Taiwan High Court
Parties to the legal matter: Michael Chang (Chairman); Youe-Kong Shue (Former Vice Chairman); Amy Hung (Former General Manager); Tony Yu (Former Chief Science Officer); Jon-Jin Liao (Former Medical Business Director) …
OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference
1. Date of the event: Jan 12, 2021 2. Time: 00:00:00 NST 3. Location: Virtual Event 4. Summary: OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference …